Novo Nordisk execs field questions from analysts at their Capital Markets Day. (Credit: Novo Nordisk)
Novo touts early data for next-gen oral weight loss drug as it outlines next steps
Novo Nordisk’s oral amycretin showed a 13.1% weight loss in patients after just 12 weeks in a small Phase I trial, the company revealed at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
